Endocrine Society Annual Meeting | Conferences

March 12, 2015

Jennifer H. Kuo, MD, director, Thyroid Biopsy Program, Columbia University, discusses a study looking at the incidence of thyroid cancer among breast cancer survivors.

March 09, 2015

Lori J. Wirth, MD, discusses an open-label extension of the phase III SELECT trial, which looked at lenvatinib versus placebo for differentiated thyroid cancer.

March 09, 2015

Poly (ADP-ribose) polymerase-1 (PARP-1) is a multifunctional, chromatin-regulating protein. PARP inhibitors are currently undergoing clinical trials as potential targeted therapies for the treatment of breast, uterine, colorectal, and ovarian cancer.

March 09, 2015

The oral androgen receptor inhibitor, enzalutamide, blocks several steps in the androgen receptor signaling pathway and prevents the entry of androgen receptor into the cell nucleus.

March 09, 2015

A recent study showed that the androgen receptor (AR) splice variant AR-V7 activated full-length AR through an alternative biosynthesis pathway and increased citrate utilization through altered metabolic activities, which may partially explain its resistance to conventional androgen deprivation therapy (ADT).

March 08, 2015

Steven I. Sherman, MD, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial.

March 08, 2015

On February 13, 2015, the FDA approved lenvatinib (Lenvima) for treatment of locally recurrent or metastatic differentiated thyroid cancer (DTC) that is refractory to radioactive iodine therapy (RAI).

March 08, 2015

Frances Carr, PhD, professor, Department of Pharmacology, The University of Vermont, discusses the relationship between the thyroid hormone receptor and Runx2 expression in thyroid cancer cells.

March 08, 2015

According to a recent descriptive analysis of the VA Corporate Data Warehouse, veterans who reported Agent Orange exposure had higher rates of thyroid cancer compared to the overall national VA health care patient population.

March 08, 2015

The incidence of thyroid cancer, which is now the most rapidly increasing endocrine malignancy, has been increasing at a rate of 3% to 5% per year, resulting in a near doubling in the past 30 years.